-transparent.png){kind=logo}
The pharmacokinetics of nifurtimox, a drug used in the treatment of Trypanosoma cruzi infections, has been studied in seven patients with chronic renal failure undergoing haemodialysis, and in seven healthy subjects. Each subject took nifurtimox 15 mg.kg-1 orally and blood samples were obtained for 10 h after administration. Nifurtimox in serum was analyzed by HPLC. The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability. An alternative explanation would be that both the distribution volume and the clearance had changed. The mean half-life in the patients with chronic renal failure was similar to that in the healthy subjects.
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
June 1988,
British journal of clinical pharmacology,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
January 1987,
Anesthesia and analgesia,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
January 1976,
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
September 1985,
International journal of clinical pharmacology, therapy, and toxicology,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
November 1983,
Anesthesiology,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
January 1989,
Clinical therapeutics,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
August 1976,
Clinical nephrology,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
January 1995,
Clinical nephrology,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
January 1980,
Therapie,
G González-Martin, and
S Thambo, and
C Paulos, and
I Vásquez, and
J Paredes
April 1987,
Clinical pharmacokinetics,
